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Abstract The deficiency of the lysosomal neuraminidase
(NEU1; sialidase) causes the storage disorder sialidosis with
symptoms ranging from eye abnormalities and neurological
disturbances to skeletal malformations, mental retardation and
early death. Sialidosis patients encompassing a wide spectrum of
clinical symptoms were screened for mutations in neu1. We
identified the same homozygous interstitial deletion (11 kb) in
two patients causing the fusion of exon 10 of CTL4 (New Gene
22; NG22) with the 3P-UTR of neu1. In one patient we found
the resulting CTL4/Neu1 fusion transcript, in the other we
detected an alternatively spliced CTL4 transcript (retention of
intron 9). / 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Sialidosis is characterised biochemically by the de¢ciency of
lysosomal neuraminidase activity [1,2] and an abnormal tissue
accumulation and urinary excretion of sialic acid-containing
compounds. According to the clinical symptoms, sialidosis
has been divided into two subtypes with di¡erent ages of
onset and severity. Sialidosis type I, also called non-dysmor-
phic type, is the mild form of the disease with late-onset,
bilateral macular cherry-red spots, progressive impaired vision
and myoclonus syndrome. The type II or dysmorphic type
with infantile onset is characterised by skeletal dysplasia, Hur-
ler-like phenotype, dysostosis multiplex, mental retardation
and hepatosplenomegaly. The severe form often manifests it-
self prenatally and presents with ascites and hydrops fetalis
(for review see [3]).
Sialidosis is an autosomal recessive disease due to lesions in
the neu1 gene that maps to the MHC-III cluster on chromo-
some 6p21.3 [4^6]. Within this cluster neu1 is closely neigh-
boured (851 bp) to the choline transporter-like protein 4 gene
(CTL4 also called NG22) [7]. Several genetic alterations have
been reported in neu1 of unrelated sialidosis patients. The
majority of mutations consist of missense mutations (20 of
26 cases) [4,6,8^11].
In view of the fact that even an intronic mutation can cause
a complete de¢ciency of the lysosomal neuraminidase [12], we
performed a sequencing-based screening of genomic DNA
from sialidosis patients. In two cases we identi¢ed the same
11 kb deletion that encompassed the entire coding region of
neu1.
2. Material and methods
2.1. Patients
Available clinical data of the patients are summarised in Table 1.
2.2. Cell culture
Skin ¢broblasts from the patients and healthy control donors were
cultured in Eagle’s modi¢ed Eagle’s medium supplemented with 10%
foetal calf serum (PAA Laboratories, Austria); non-essential amino
acids were added as described previously [13].
2.3. Enzyme activity assay
Enzyme activity of lysosomal neuraminidase was determined using
2P-4-methylumbelliferyl-K-N-acetylneuramic acid as substrate accord-
ing to [14]. The L-galactosidase activity was measured according to
Gehler et al. [15]. Activities are expressed as speci¢c activities based
on the protein content of the samples that was determined using the
Lowry procedure [16].
2.4. Isolation of genomic DNA and total RNA
Genomic DNA and total RNA were isolated from cultured skin
¢broblast using the QIAamp DNA Mini Kit and the RNeasy Kit
(Qiagen, Germany).
2.5. Polymerase chain reaction (PCR) ampli¢cation and direct
sequencing
Genomic DNA was ampli¢ed with exon-speci¢c oligonucleotides as
described previously [8]. PCR for the intronic sequences was per-
formed using combinations of the same oligonucleotides. Ampli¢ca-
tion of cDNA was carried out with three overlapping sets of oligo-
nucleotides encompassing the entire coding region of the human
lysosomal neuraminidase mRNA [6]. After puri¢cation the PCR frag-
ments were sequenced directly in the forward and reverse directions
on an Applied Biosystems 377-18 DNA sequencer using the Big Dye
Termination Kit (Applied Biosystems, USA) and the corresponding
oligonucleotides.
2.6. Reverse transcription (RT)-PCR and duplex-PCR
Reverse transcriptions were carried out with 1 Wg DNase I treated
total RNA in the presence of a RNAse inhibitor using the SuperScript
II reverse transcriptase (Life Technologies, USA). Expression of the
mature mRNAs of neu1 and the protective protein cathepsin A
(PPCA) were investigated by ampli¢cations of oligo(dT) primed
cDNA using exon-speci¢c primers. For ampli¢cation of pre-mRNA
of neu1 we performed PCR with random hexamer primed cDNA and
intron C-speci¢c primers (Table 2). RT-PCR products were electro-
phoretically separated on an ethidium bromide stained 2% agarose gel
and documented by digitalisation (Gel documentation system, Hero-
lab, Germany).
To determine the heterozygosity of the 11 kb deletion (g.38042^
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+3261 del) in the sister of patient 1, we performed a duplex-PCR with
genomic DNA using one forward primer and two reverse primers
(Table 2).
2.7. Transcriptional activity of the CTL4/Neu1 fusion gene
Based on the genomic sequencing data from both patients a hypo-
thetical fusion transcript was assumed to consist of exons 1^10 of the
CTL4 gene and the 3P-UTR of neu1. Transcription of the CTL4/Neu1
fusion gene was investigated by nested RT-PCR with two forward
primers located within the CTL4 part and two reverse primers in
the neu1 part of the fusion transcript (Table 2). Sequencing of the
PCR product detected in patient 1 con¢rmed the occurrence of the
CTL4/Neu1 fusion transcript. As we obtained no ampli¢cation prod-
ucts in the sister of patient 1 and patient 2 a nested RT-PCR was
performed using primers speci¢c for the CTL4 part of the calculated
fusion transcript. Here, the inner forward primer corresponded to the
border of the exons 6 and 7 and both reverse primers were located
within the remaining part of exon 10. In patient 2 a signi¢cantly
longer PCR product was observed and sequenced.
3. Results
3.1. Activities of lysosomal neuraminidase and L-galactosidase
in sialidosis patients
The lysosomal neuraminidase activities of ¢broblasts de-
rived from sialidosis patients were determined and compared
to the activities of healthy controls (Table 1). The ¢broblasts
from both patients exhibited a complete lack of NEU1 activ-
ity. The activity of L-galactosidase was normal in both cases.
3.2. RNA expression of lysosomal neuraminidase and PPCA
The pre-mRNA and mRNA expression of neu1 in sialidosis
patients were investigated by RT-PCR. No pre-mRNA or
mature mRNA was detectable in both patients, whereas the
transcriptional activity of the PPCA gene was normal (Fig. 1).
3.3. Localisation of the 11 kb deletion
Ampli¢cations of the genomic and cDNA derived from the
patients with primer combinations speci¢c for neu1 failed to
generate any detectable PCR products. Screening of the entire
neu1 gene and of the neighbouring upstream and downstream
regions using primers located between g.38992 and g.38218,
and between g.+5024 and g.+6056, relative to the start ad-
enine of neu1 led to the re-occurrence of a PCR product.
Based on these ¢ndings, PCR was performed using a forward
Table 1
Clinical and biochemical data of the patients
Patient 1 Patient 2
Clinical type II II
Age at diagnosis prenatal prenatal
Sex male male
Ethnicity Turkish Turkish
Clinical features
Hydrops fetalis + +
Hepatomegaly + +
Ascites + +
Other symptoms polydactyly
Enzyme activitiesa
NEU1 0 0
L-Galactosidase 21.2 mU/mg protein 16.3 mU/mg protein
aThe normal range of healthy individuals for NEU1 (n=6) was
1.29^2.56 mU/mg protein and 9.16^27.28 mU/mg protein for L-ga-
lactosidase (n=22). 1 mU corresponds to 1 nmol substrate cleaved
per min.
Table 2
Oligonucleotides used for mutation analysis
Primer Sequence Position
RT-PCR
f-neu1-a 5P-CGCTACGGAAGTGGGGTCAG-3P +2261 to +2280a
r-neu1-a 5P-AGTCCTGAAGGCAGAATACC-3P +3097 to +3078a
f-IN-C (neu1) 5P-GCTGCCTTGTGGAGAGTCTG-3P +1619 to +1638a
r-IN-C (neu1) 5P-GGAACTGGGTGTCACAGAAGGAG-3P +2144 to +2122a
f-PPCA-a 5P-CCTCAACATCTACAATCTCTATGCC-3P +813 to +837c
r-PPCA-a 5P-CAGTATGGCTGCTTGTTCAGGA-3P +1442 to +1421c
f-CTL4-a 5P-GATTGTGGCCTGGTTGTATGGAG-3P +156 to +178b
f-CTL4-b 5P-GGGAGAACAAAGATAAGCCGTAT-3P +233 to +255b
f-CTL4-c 5P-TAGGTTACATCGTGGTGGGGAT-3P +94 to +113b
f-CTL4-d 5P-TGCTCCAGCTCTGGGACGC-3P +522 to +540b
r-CTL4-a 5P-GCAGTAGTAGATGCCATATGCCAG-3P +805 to +828b
r-CTL4-b 5P-GAAGCAAGATAAACAGTAGGCTCAAG-3P +723 to +748b
r-CTL4-c 5P-CTCCTGCACGCTCTGGTAG-3P +903 to +921b
f-GAPDH-a 5P-GATGCTGGCGCTGAGTACGTC-3P +339 to +360d
r-GAPDH-a 5P-CGTTGTCATACCAGGAAATGAGC-3P +1024 to +1002d
Fusion transcript CTL4/NEU1
f-CTL4-a see above +156 to +178b
r-neu1-b 5P-CCCAAGACAGGACCAATCAATGTC-3P +3330 to +3353a
f-CTL4-b see above +233 to +255b
r-neu1-c 5P-CCCAAGACAGGACCAATCAATGTC-3P +3263 to +3287a
Duplex PCR
f-CTL4/neu1 5P-CCATGGACCAACATTACTCCACC-3P 38764 to 38787a
r-primer 1 5P-CCCTCTAGAAGGCCTATGTCATATTC-3P 37574 to 37599a
r-primer 2 5P-CTACAGCTCACTAGACCTGCC-3P +3352 to +3332a
Additional sequencing primer
f-neu1-8242 5P-AGCCTACTGTTTATCTTGCTTCTGC-3P 38242 to 38218a
r-neu1+3606 5P-GATGTGCATTGACAGAACCATAGAGA-3P +3606 to +3581a
aPosition relative to the start ATG of the genomic DNA sequence (accession number AF134726).
bPosition relative to the start ATG of the mRNA sequence (accession number XM_016669).
cPosition relative to the start ATG of the mRNA sequence (accession number NM_000308).
dPosition relative to the start ATG of the mRNA sequence (accession number XM_006959).
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primer (f-neu138242) upstream of the assumed deletion (V11
kb) and a reverse primer (r-neu1+3606) within the 3P-UTR of
neu1. Details regarding this ampli¢cation procedure are
shown in Fig. 2A. Direct sequencing of the obtained PCR
products con¢rmed the expected 11 kb deletion. The break-
points of the deletion were located between the nucleotides
g.38041 and g.38042 (relative to the start adenine of neu1)
in exon 10 of the CTL4 gene and g.+3261 and g.+3262 (Fig.
2B) in the 3P-UTR of neu1. Taken together, genomic sequenc-
ing and the complete lack of neu1 transcripts suggested ho-
mozygosity of this gross deletion in both patients. In the 3P-
UTR of neu1 another small deletion was observed in both
patients (c.*1566^1570delTGAAT, data not shown).
3.4. Allelic status of patients a¡ected by the gross deletion
We performed a duplex PCR using one forward and two
reverse primers in the same reaction to con¢rm the allelic
status for the 11 kb deletion in patients 1 and 2 and in the
sister of patient 1 (Fig. 3). Subsequent gel electrophoresis
revealed the occurrence of two di¡erent fragments in the sister
of patient 1. The normal allele was represented by the 1190 bp
fragment and the deletion-containing allele by the 790 bp
PCR product indicating heterozygosity for this alteration. In
contrast, the patients showed only the 790 bp fragment spe-
ci¢c for the deletion, an unrelated control donor exhibited
only the 1190 bp product.
3.5. Transcription of the CTL4/neu1 fusion gene
We performed an RT-PCR to verify the occurrence of the
CTL4/neu1 fusion transcript (GenBank accession number
AF466766). Interestingly, only in patient 1 was the fusion
transcript detected (Fig. 4A) and subsequently con¢rmed by
direct sequencing. Nested RT-PCR was necessary to yield a
detectable product for CTL4 cDNA, indicating a low level
transcription of CTL4 mRNA in human ¢broblasts. The
nested ampli¢cation with outer primers speci¢c for a CTL4
Fig. 1. RT-PCR analysis of neu1 pre- and mature mRNA and
PPCA mRNA in the sialidosis patients (P1, P2). GAPDH mRNA
was used as control. C1^C4: control individuals.
Fig. 2. Characterisation of the 11 kb deletion. A: Gel electrophore-
sis of a PCR using primers located on either side of the interstitial
deletion of patient 1 (P1), his sister (SP1) and patient 2 (P2). The
scheme above displays the closely neighboured genes CTL4 and
neu1 (black boxes: exons, white boxes: introns), the exact range
and localisation of the deletion and the positions of the used prim-
ers (arrows). B: Genomic sequence of the fusion region.
Fig. 3. Duplex PCR analysis of the allelic status of the a¡ected pa-
tients. Top: Localisation and expected product length of the three
primers used. Bottom: Gel electrophoresis showing the obtained
PCR products. In the control (C) only the non-deletion-speci¢c
1190 bp fragment was observed. The 790 bp fragment ampli¢ed
from both patients (P1 and P2) indicates the homozygous deletion.
The sister of patient 1 (SP1) is heterozygous.
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transcript ranging from exon 3 to the end of exon 10 and
subsequent inner primers for a transcript from the end of
exon 7 to the end of exon 10 resulted in a PCR product in
both patient 1 and his sister, but not in patient 2 (data not
shown). However, using an outer forward primer from the
end of exon 3, and an inner forward primer from the end
of exon 4 in combination with two di¡erent reverse primers
corresponding to the beginning and the centre of exon 10
revealed a substantially longer PCR product in patient 2 com-
pared to the control (Fig. 4B). Sequencing identi¢ed the re-
tention of intron 9 in the CTL4 transcript of patient 2.
4. Discussion
Since cloning of the cDNA of the lysosomal neuraminidase,
several studies had characterised mutational alterations of
neu1 and attempts were made to correlate the impact of the
mutations with the clinical phenotypes. The catalytic activity
of the lysosomal neuraminidase relies on the formation of a
quaternary complex with active L-galactosidase, N-acetylga-
lactosamine-6-sulphate sulfatase, and PPCA. The de¢ciency
of lysosomal neuraminidase is associated with two di¡erent
disorders of lysosomal metabolism: sialidosis and galactosia-
lidosis [17]. Since both sialidosis and galactosialidosis are
characterised by similar phenotypes, we excluded the possibil-
ity of galactosialidosis by determining the enzyme activity of
L-galactosidase in the investigated patients. Both patients
showed a total loss of neuraminidase activity that corre-
sponded to their severe mutational alterations. Additionally,
no pre-mRNA and mature mRNA of neu1 were detectable in
both patients. The ¢nding of a total lack of neu1 transcripts in
our patients is in contrast to the cases so far published
[4,6,9,10,12]. It was suggested that a complete absence of ly-
sosomal neuraminidase is lethal during foetal development or
at birth [9]. This hypothesis is con¢rmed by our ¢ndings in
both patients who died shortly after birth. The complete ab-
sence of neu1 transcripts in these patients is unambiguously
caused by the observed homozygous gross deletion since it
encompasses the entire coding and promotor regions of the
neu1 gene. The healthy sister of patient 1 was determined as a
heterozygous carrier of the same deletion. The deletion also
a¡ects the CTL4 gene (NG22, GenBank accession number
XM_016669), which is located 851 bp centromeric from
neu1 on chromosome 6p21.3. The CTL4 gene was sequenced
as part of the gene-rich MHC-III cluster and consists of 21
exons coding for a hypothetical protein of 712 amino acids
with as yet unknown function. The deduced polypeptide
shares properties of a receptor-like protein such as several
transmembrane domains and potential glycosylation sites [7].
The deletion leads to a genomic rearrangement between exon
10 of CTL4 and the 3P-UTR of neu1. Analysis of the tran-
scriptional activity of the CTL4/Neu1 fusion gene revealed
di¡erent consequences of the same deletion in the three af-
fected cases. In patient 1, the assumed CTL4/Neu1 fusion
transcript was observed, indicative for the existence of a fu-
sion protein. In his heterozygous sister only the normal tran-
scripts of CTL4 and neu1 were detectable concordant with the
complete absence of clinical symptoms. In patient 2, we did
not observe the fusion transcript, but found a retention of
intron 9 in the CTL4 mRNA. The reason for this alternatively
spliced CTL4 mRNA apparently terminating transcription
before the fusion site remains unclear, since we could not
Fig. 4. Transcriptional activity of the CTL4/Neu1 fusion gene. A: RT-PCR with primers speci¢c for the CTL4/neu1 fusion transcript. The fu-
sion transcript was only detected in patient 1 and veri¢ed by direct sequencing. B: With a reverse primer located in the beginning of exon 10
of CTL4, an enlarged fragment was ampli¢ed from patient 2. Sequencing revealed the retention of intron 9.
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detect any alterations within the surrounding splice sites. Both
patients were prenatally diagnosed by enzyme activity assays
and exhibited a particularly severe clinical phenotype with
hydrops fetalis and ascites. Additionally, only in patient 1
polydactyly was observed. Whether di¡erent clinical symp-
toms might be due to a di¡erent loss of CTL4 protein func-
tion cannot be addressed with the present data and requires
more information about the physiological function of CTL4.
In view of the fact that the parents of patient 1 and 2 and
sister of patient 2 are heterozygous carriers of the deletion, yet
are completely healthy, a partial loss of the CTL4 protein
appears to have no clinical consequences.
Acknowledgements: We thank H. Dietrich and N. Blenck for excellent
technical expertise, Dr. W. Kachel and colleagues (Children’s Hospital
Heilbronn, Germany) for providing ¢broblasts of patient 1 and Dr.
H.-D. Rott and colleagues (Institute of Human Genetics, University
of Erlangen, Germany) for cooperating in the case of patient 2.
References
[1] Cantz, M., Gehler, J. and Spranger, J. (1977) Biochem. Biophys.
Res. Commun. 74, 732^738.
[2] Spranger, J., Gehler, J. and Cantz, M. (1977) Am. J. Med. Genet.
1, 21^29.
[3] Thomas, G.H. (2001) in: The Metabolic and Molecular Bases of
Inherited Disease (Scriver, C.R., Beaudet, A.L., Sly, W.S. and
Valle, D., Eds.), Vol. 3, pp. 3507^3533, McGraw-Hill, New
York.
[4] Bonten, E., van der Spoel, A., Fornerod, M., Grosveld, G. and
d’Azzo, A. (1996) Genes Dev. 10, 3156^3169.
[5] Milner, C.M., Smith, S.V., Carrillo, M.B., Taylor, G.L., Hollins-
head, M. and Campbell, R.D. (1997) J. Biol. Chem. 272, 4549^
4558.
[6] Pshezhetsky, A.V., Richard, C., Michaud, L., Igdoura, S., Wang,
S., Elsliger, M.A., Qu, J., Leclerc, D., Gravel, R., Dallaire, L.
and Potier, M. (1997) Nat. Genet. 15, 316^320.
[7] O’Regan, S., Trai¡ort, E., Ruat, M., Cha, N., Compaore, D. and
Meunier, F.M. (2000) Proc. Natl. Acad. Sci. USA 97, 1835^1840.
[8] Lukong, K.E., Elsliger, M.A., Chang, Y., Richard, C., Thomas,
G., Carey, W., Tylki-Szymanska, A., Czartoryska, B., Buchholz,
T., Criado, G.R., Palmeri, S. and Pshezhetsky, A.V. (2000) Hum.
Mol. Genet. 9, 1075^1085.
[9] Bonten, E.J., Arts, W.F., Beck, M., Covanis, A., Donati, M.A.,
Parini, R., Zammarchi, E. and d’Azzo, A. (2000) Hum. Mol.
Genet. 9, 2715^2725.
[10] Naganawa, Y., Itoh, K., Shimmoto, M., Takiguchi, K., Doi, H.,
Nishizawa, Y., Kobayashi, T., Kamei, S., Lukong, K.E., Pshe-
zhetsky, A.V. and Sakuraba, H. (2000) J. Hum. Genet. 45, 241^
249.
[11] Itoh, K., Naganawa, Y., Matsuzawa, F., Aikawa, S., Doi, H.,
Sasagasako, N., Yamada, T., Kira, J., Kobayashi, T., Pshezhet-
sky, A.V. and Sakuraba, H. (2002) J. Hum. Genet. 47, 29^37.
[12] Penzel, R., Uhl, J., Kopitz, J., Beck, M., Otto, H.F. and Cantz,
M. (2001) FEBS Lett. 501, 135^138.
[13] Cantz, M., Kresse, H., Barton, R.W. and Neufeld, E.F. (1972)
Methods Enzymol. 28, 884^887.
[14] Harzer, K., Cantz, M., Sewell, A.C., Dhareshwar, S.S., Roggen-
dorf, W., Heckl, R.W., Schofer, O., Thumler, R., Pei¡er, J. and
Schlote, W. (1986) Hum. Genet. 74, 209^214.
[15] Gehler, J., Cantz, M., Stoeckenius, M. and Spranger, J. (1976)
Eur. J. Pediatr. 122, 201^206.
[16] Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J.
(1951) J. Biol. Chem. 193, 265^275.
[17] Pshezhetsky, A.V. and Ashmarina, M. (2001) Prog. Nucleic Acid
Res. Mol. Biol. 69, 81^114.
FEBS 26104 7-6-02 Cyaan Magenta Geel Zwart
J. Uhl et al./FEBS Letters 521 (2002) 19^23 23
